# Clinical Trials Data ERBB2 - Document 10

# Prognostic Relevance of Biological Subtype in Breast Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT02063906

"eligibilityCriteria": "Inclusion Criteria:\n\n\* patients who received curative surgery\n\* stage I-III breast cancer\n\* between January 2004 and September 2008\n\* had available immunohistochemistry profiles.\n\nexclusion Criteria:\n\n\* age \\<18 years old\n\* microinvasive carcinoma of breast",  
 "healthyVolunteers": false,  
 "sex": "FEMALE",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients who received curative surgery for stage I-III breast cancer between January 2004 and September 2008 and had available immunohistochemistry profiles.",

Question:  
Based on the following clinical trial information, would a patient with a ERBB2 gene mutation be eligible for the clinical trial?

Answer:  
This trial information \*\*does not mention ERBB2 (HER2) status\*\* as either an inclusion or exclusion criterion. Therefore, we cannot determine if a patient with an ERBB2 mutation would be eligible based on this information alone. They \*might\* be eligible if they meet all other criteria, but further information about the trial is needed.